Cannabics Pharmaceuticals Inc. announced the launching of a new research program for the development of a Breast Cancer antitumor targeting medicine. The announcement comes following the launching of a Melanoma research program in April 2021, and as the company is gearing up for submission of a pre-IND meeting package and meeting request to the US Food and Drug Administration regarding its Colorectal Cancer treatment drug candidate RCC-33. Breast cancer is the most common invasive cancer in women, and it is the most commonly diagnosed type of cancer globally along with lung cancer. According to the World Health Organization, in 2020, approximately 2.3M cases of Breast Cancer were diagnosed worldwide, and some 685,000 related deaths occurred globally.